logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home

Pomegranate Health Cloud's application for an IPO in the United States has been filed.

date
17:09 17/01/2025
avatar
GMT Eight
Pomegranate Cloud Healthcare is going to the United States for an IPO and has been approved.
On January 17, the China Securities Regulatory Commission issued the "Notice on the Overseas Issuance and Listing Filing of POMDOCTOR LIMITED (Pomegranate Cloud Medical Co., Ltd.). Pomegranate Cloud Medical plans to issue no more than 1,007,113 common shares and list on the Nasdaq Stock Exchange in the United States.
Related Articles
HK Stock
In February, the sales volume of Q TECH (01478) mobile camera modules was 32.116 million units, an increase of 40.2% year-on-year.
HK Stock
YANCHANG PETRO (00346) issues profit warning, expecting a loss of approximately HK$780 million in 2025 compared to a profit in the previous year.
China Stock
Jiangsu Hengrui Pharmaceuticals(600276.SH): Injection SHR-9803 obtains drug clinical trial approval letter.
In February, the sales volume of Q TECH (01478) mobile camera modules was 32.116 million units, an increase of 40.2% year-on-year.
HK Stock
YANCHANG PETRO (00346) issues profit warning, expecting a loss of approximately HK$780 million in 2025 compared to a profit in the previous year.
HK Stock
Jiangsu Hengrui Pharmaceuticals(600276.SH): Injection SHR-9803 obtains drug clinical trial approval letter.
China Stock
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
icon
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
icon
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
icon
11/03/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.